Aptamer and Neuro-Bio enter the second phase of Alzheimer’s test development

Aptamer Group plc, the developer of novel Optimer binders to enable innovation in the life sciences industry, announces the second phase of its on-going partnership with Neuro-Bio, an Oxfordshire-based biotechnology company with a therapeutic focus on neurodegenerative disease, to develop Optimer binders for a lateral flow test for the early diagnosis of Alzheimer’s disease.

This latest phase involves development of an additional Optimer binder against the innovative Neuro-Bio target implicated in Alzheimer’s disease, with the goal of developing reagents for a lateral flow test for early disease detection. Following the earlier identification of Optimer binders to this novel Alzheimer’s disease biomarker, these binders have been characterised for use in lateral flow and biosensor assays.

Common lateral flow test formats require a pair of binders to increase diagnostic test accuracy. To prevent the need for animal-derived antibodies in its Alzheimer’s disease diagnostic, Neuro-Bio now requires the development of additional binders to support the lateral flow test format and deliver a wholly Optimer-powered test. As Optimer binders are oligonucleotide-based, rather than protein-based like antibodies, they offer further advantages including scalability of manufacture, improved shelf-life and tuneability benefits that will allow more stable and specific reagents for use in lateral flow tests.

“We are very pleased to continue our exciting relationship with Neuro-Bio to deliver the specific Optimer binders needed to enable this revolutionary diagnostic for this devastating disease. It is great to work with such enthusiastic partners that understand our Optimer technology’s benefits and are actively seeking solutions to overcome the industry’s problems with antibodies.”

Steve Hull, Chairman of Aptamer Group

 

“At Neuro-Bio we’re thrilled at entering this next phase of development with Aptamer Group: the first phase proved productive and very promising. Now, this next stage takes us closer to realising a highly novel and much needed technology for detecting neurodegenerative diseases at a very early stage.”

Baroness Susan Greenfield, CEO of Neuro-Bio

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Aptamer Group. (2024, February 22). Aptamer and Neuro-Bio enter the second phase of Alzheimer’s test development. News-Medical. Retrieved on April 17, 2024 from https://www.news-medical.net/news/20240222/Aptamer-and-Neuro-Bio-enter-the-second-phase-of-Alzheimere28099s-test-development.aspx.

  • MLA

    Aptamer Group. "Aptamer and Neuro-Bio enter the second phase of Alzheimer’s test development". News-Medical. 17 April 2024. <https://www.news-medical.net/news/20240222/Aptamer-and-Neuro-Bio-enter-the-second-phase-of-Alzheimere28099s-test-development.aspx>.

  • Chicago

    Aptamer Group. "Aptamer and Neuro-Bio enter the second phase of Alzheimer’s test development". News-Medical. https://www.news-medical.net/news/20240222/Aptamer-and-Neuro-Bio-enter-the-second-phase-of-Alzheimere28099s-test-development.aspx. (accessed April 17, 2024).

  • Harvard

    Aptamer Group. 2024. Aptamer and Neuro-Bio enter the second phase of Alzheimer’s test development. News-Medical, viewed 17 April 2024, https://www.news-medical.net/news/20240222/Aptamer-and-Neuro-Bio-enter-the-second-phase-of-Alzheimere28099s-test-development.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Aptamer Group and Bio-Works Technologies partner to enable improved solutions for gene therapy manufacturing